Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 28 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
- 28 Sep 2017 Planned End Date changed from 1 Feb 2019 to 1 Aug 2020.
- 09 Oct 2015 Planned end date changed from 1 Feb 2018 to 1 Feb 2019, as reported by ClinicalTrials.gov.